Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

817
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
817
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

288
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
288
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.4K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

602
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
602
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.9K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year.

The British journal of dermatology·2026
Same author

Dupilumab is Effective in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.

Journal of asthma and allergy·2026
Same author

Atopic dermatitis Yardstick: A new era of topical and systemic treatments.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).

Pediatric dermatology·2026
Same author

Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025

Related Experiment Video

Updated: Feb 19, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.7K

Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines.

Mark Boguniewicz1

  • 1Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colo.

The Journal of Allergy and Clinical Immunology. in Practice
|November 11, 2017
PubMed
Summary

Atopic dermatitis (AD) is a chronic skin disease affecting adults and children. Research highlights its systemic nature and explores novel biologic treatments targeting immune pathways.

Keywords:
Atopic dermatitisBiologicsComorbiditiesDupilumabEczemaImmune dysregulation

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.5K

Related Experiment Videos

Last Updated: Feb 19, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.7K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.5K

Area of Science:

  • Dermatology
  • Immunology
  • Genetics

Background:

  • Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition impacting global health.
  • AD affects both children and adults, with persistent, relapsing, or new-onset courses.
  • Comorbidities, both atopic and non-atopic, are increasingly associated with AD.

Purpose of the Study:

  • To investigate the systemic nature of atopic dermatitis.
  • To identify immune dysregulation and epidermal barrier dysfunction in AD.
  • To explore novel biologic therapeutic targets for AD.

Main Methods:

  • Analysis of immune and inflammatory markers in circulation.
  • Assessment of keratinocyte differentiation defects in nonlesional skin.
  • Review of current clinical trials for novel AD biologics.

Main Results:

  • AD exhibits systemic immune abnormalities and epidermal barrier defects.
  • Multiple cytokine pathways, including TH1, TH22, and TH17/IL-23, are implicated beyond type 2 immunity.
  • Dupilumab, targeting IL-4Rα, is the first approved biologic for moderate-to-severe adult AD.

Conclusions:

  • Atopic dermatitis is a systemic disease with significant translational implications.
  • Targeting specific immune pathways offers promising therapeutic strategies for AD.
  • Ongoing research focuses on biologics targeting IL-4/IL-13, IL-31, and IL-12/IL-23.